Breast cancer indication for bevacizumab

Breast cancer indication for bevacizumab

The Oncologic Drugs Advisory committee of the FDA has recommended removing the indication for breast cancer treatment for bevacizumab (Avastin^®). The 12-1 vote was made after data were presented that the drug provided no survival benefit when used in combination with docetaxel, while contributing significant adverse effects. Bevacizumab, a humanized monoclonal antibody, which blocks new blood vessel formation (angiogenesis inhibitor), also carries indications for treatment of colon, lung, kidney, and brain cancers.